Clinical trials: Diseases of the Urinary System
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents…
- Trial name
- NCT00224042
- Testing
- Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Watson Pharmaceuticals
Urge Incontinence, Urinary Retention
Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control
The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.
- Trial name
- NCT00225966
- Testing
- Device Medtronic InterStim Tined Leads Models 3889 and 3093
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH
Renal Impairment
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
- Trial name
- NCT02852239
- Testing
- dabrafenib
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Renal Disease
OPTIMISE-CKD Study_current Clinical Landscape in Spain
OPTIMISE-CKD is a retrospective, observational study, using secondary data. The incidence of renal disease, including CKD, using eGFR or UACR laboratory measurements and diagnostic codes will be assessed in the study population.
- Trial name
- NCT06614712
- Testing
- Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024), Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)
- Where
- Spain
- Volunteers
- 91,628 people
- Sponsor
- AstraZeneca
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Kidney Diseases
Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
The study is planned to study specificity of the clinical course and treatment outcomes of C3 glomerulopathy (C3G) and Immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged under 18 years and 18 years…
- Trial name
- CRYSTAL (NCT06851845)
- Testing
- No intervention
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Anemia Associated With Chronic Kidney Disease
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who…
- Trial name
- NCT04621331
- Testing
- Roxadustat
- Where
- 4 sites in United States
- Sponsor
- Kyntra Bio
Acute Kidney Injury
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at…
- Trial name
- NCT06602453
- Testing
- GDC-8264
- Where
- 34 sites in United States, Australia and 10 more
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Growth Hormone Deficiency, Turner Syndrome
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal…
- Conditions
- Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age
- Trial name
- LGS (NCT01604395)
- Where
- South Korea
- Volunteers
- 6,000 people
- Sponsor
- LG Chem
Nocturnal Enuresis
PureWick™ France and U.S. At-Home Pilot Study
In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence…
- Trial name
- NCT05710718
- Testing
- PureWick™ System, Hollister® Female Urinary Pouch External Collection Device
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- C. R. Bard
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes
- Trial name
- TREASURE-CKD (NCT05536804)
- Testing
- Tirzepatide
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 134 people
- Sponsor
- Eli Lilly and Company
Lupus Nephritis
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
- Trial name
- NCT03943147
- Testing
- BMS-986165, Mycophenolate Mofetil
- Where
- 100 sites in United States, Australia and 14 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Renal Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.
- Trial name
- NCT01148368
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Renal Impairment
Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal function
- Trial name
- NCT04249908
- Testing
- Besifovir Dipivoxil Maleate
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Renal Artery Stenosis
Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting
The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow ups at 2, 6, 12 months and 3 years.
- Trial name
- RADAR (NCT00640406)
- Testing
- Dynamic Renal Stent plus Best Medical Treatment, Best Medical Treatment
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Biotronik AG
Carcinoma, Renal Cell
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one…
- Trial name
- NCT00338884
- Testing
- Sunitinib malate
- Where
- 15 sites in Argentina, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Bladder Cancer, Transitional Cell Carcinoma
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin.
- Conditions
- Bladder Cancer, Transitional Cell Carcinoma, Metastasis
- Trial name
- NCT00389155
- Testing
- Vinflunine, Gemcitabine
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb